From: Preimplantation genetic testing for BRCA gene mutation carriers: a cost effectiveness analysis
Probability | Description | Probability | Range assumed |
---|---|---|---|
P1 | Probability of male newborn | 0.5 | Â |
P2 | Probability newborn is BRCA carrier | 0.5 | Â |
P3 | Probability that a non-carrier will experience ovarian cancer 13 | 0.0128 | 0.0005-0.0989 |
P4 | Probability that a non- carrier will experience breast cancer14 | 0.13 | 0.11-0.14 |
P5 | Probability that carrier will undergo RRSO 20,21 | 0.65 | 0.3-0.75 |
P6 | Probability that BRCA carrier will undergo RRM 25 | 0.16 | 0.13-0.3 |
P7 | Reduction in risk of ovarian cancer from RRSO 26,27 | 0.8 | 0.8-0.96 |
P8 | Probability that BRCA carrier without RRSO will get OC 28 | 0.2987 | 0.24-0.35 |
P9 | Reduction in risk of breast cancer from RRM and RRSO27 | 0.91 | 0.78-0.99 |
P10 | Probability that a BRCA carrier without RRM will experience breast cancer 28 | 0.53 | 0.44-0.62 |
P11 | Reduction in risk of breast cancer from RRSO 22,24,29 | 0.0 | 0.37-0.65 |
P12 | Reduction in breast cancer risk from RRM without RRSO 30 | 0.91 | 0.62-0.98 |
P13 | Probability of live newborn with IVF/PGD (1 cycles of fresh ET and 2 cycles of thawed ET) | 0.84 | 0.7-0.9 |